Currently viewing the tag: "Werfern group"
In march 2011, Bioporto signed the first non-exclusive license agreement for access to the NGAL cut-off patent.
The deal was made with US based Instrumentation Laboratory (part of the Werfen Group), and paid an initial 250.000€, rising to 2.000.000€ in milestones. The deal also holds a 5,5% royalty for Bioporto.
More important though, entering […]
Ongoing debate
- James Rolitson on Good Discussion on Bronte Capital’s long thesis on Herbalife
- Thomas Goldberg on Good Discussion on Bronte Capital’s long thesis on Herbalife
- Spekulant.dk on dashboard
- Muldyr on dashboard
- kasperlindvig on dashboard

